Stock Track | 3SBio Soars 5.05% Intraday on Strong 2025 Earnings and Undervaluation Appeal
Stock Track
Apr 13
3SBio's stock price surged 5.05% during intraday trading on Monday, marking a significant upward movement for the biopharmaceutical company.
The sharp rise appears driven by the company's recently reported strong financial performance for 2025, which included sales of CNY 17,695.75 million and net income of CNY 8,482.16 million. Investors also responded positively to the company's reaffirmed final dividend, highlighting a commitment to returning cash to shareholders. Analyst commentary further supported the move, noting the stock trades at a P/E ratio of just 5.9x, which is considered undervalued compared to an estimated fair P/E of 10.4x and significantly below industry peer averages.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.